NASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis $68.81 -0.98 (-1.40%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$68.68 -0.13 (-0.19%) As of 05/22/2026 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PTC Therapeutics Stock (NASDAQ:PTCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTC Therapeutics alerts:Sign Up Key Stats Today's Range$68.26▼$70.7450-Day Range$63.36▼$76.8552-Week Range$43.17▼$87.50Volume715,145 shsAverage Volume1.58 million shsMarket Capitalization$5.71 billionP/E RatioN/ADividend YieldN/APrice Target$88.36Consensus RatingModerate Buy Company Overview PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options. Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets. The company also commercializes Emflaza (deflazacort) for patients with Duchenne muscular dystrophy, expanding its portfolio in neuromuscular disease. PTC’s pipeline extends into areas such as central nervous system disorders and metabolic diseases, with programs advancing through clinical and preclinical stages to address rare forms of Rett syndrome, tyrosinemia and other genetic conditions. Headquartered in South Plainfield, New Jersey, PTC operates a global network encompassing commercial, research and manufacturing facilities across North America, Europe and Asia. The company’s leadership team is led by Stuart W. Peltz, Ph.D., who has served as Chief Executive Officer since co-founding the business. Under his guidance, PTC has established strategic collaborations and regulatory approvals that bolster its presence in key international markets, reflecting a commitment to bringing innovative therapies to patients around the world.AI Generated. May Contain Errors. Read More PTC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScorePTCT MarketRank™: PTC Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 182nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingPTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 8 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialPTC Therapeutics has a consensus price target of $88.36, representing about 28.4% upside from its current price of $68.81.Amount of Analyst CoveragePTC Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PTC Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth921.05% Earnings GrowthEarnings for PTC Therapeutics are expected to grow by 921.05% in the coming year, from $0.19 to $1.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -29.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -29.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioPTC Therapeutics has a PEG Ratio of 12.83. PEG Ratios above 1 indicate that a company could be overvalued.Read more about PTC Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.45% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 7.44.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 14.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.01 News SentimentPTC Therapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for PTC Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,925,979.00 in company stock.Percentage Held by Insiders5.50% of the stock of PTC Therapeutics is held by insiders.Percentage Held by InstitutionsPTC Therapeutics has minimal institutional ownership at this time.Read more about PTC Therapeutics' insider trading history. Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTCT Stock News HeadlinesMark Elliott Boulding Sells 2,812 Shares of PTC Therapeutics (NASDAQ:PTCT) StockMay 20, 2026 | insidertrades.comMatthew Klein Sells 12,572 Shares of PTC Therapeutics (NASDAQ:PTCT) StockMay 17, 2026 | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 24 at 1:00 AM | Profits Run (Ad)PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 12,572 SharesMay 16, 2026 | insidertrades.comPTC Therapeutics Stock Short Interest Report | NASDAQ:PTCT | BenzingaMay 15, 2026 | benzinga.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 13, 2026 | americanbankingnews.comPTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells 2,850 Shares of StockApril 24, 2026 | insidertrades.comSee More Headlines PTCT Stock Analysis - Frequently Asked Questions How have PTCT shares performed this year? PTC Therapeutics' stock was trading at $75.96 at the beginning of the year. Since then, PTCT shares have decreased by 9.4% and is now trading at $68.81. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.42. The company's revenue for the quarter was up 43.5% on a year-over-year basis. Read the conference call transcript. When did PTC Therapeutics IPO? PTC Therapeutics (PTCT) raised $121 million in an initial public offering (IPO) on Thursday, June 20th 2013. The company issued 8,372,000 shares at a price of $13.00-$16.00 per share. Who are PTC Therapeutics' major shareholders? Top institutional shareholders of PTC Therapeutics include Janus Henderson Group PLC (8.67%), Bank of America Corp DE (2.27%), Pictet Asset Management Holding SA (1.43%) and Dimensional Fund Advisors LP (1.07%). Insiders that own company stock include Matthew B Klein, Michael Schmertzler, Mark Elliott Boulding, Pierre Gravier, Lee Scott Golden, Eric Pauwels, Christine Marie Utter, Neil Gregory Almstead, Glenn Md Phd Steele Jr, Allan Steven Jacobson, David P Southwell, Jerome B Zeldis, Emma Reeve, Alethia Young and Stephanie Okey. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD). Company Calendar Last Earnings5/07/2026Today5/24/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, PTCT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTCT CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year Founded1998Price Target and Rating Average Price Target for PTC Therapeutics$88.36 High Price Target$120.00 Low Price Target$50.00 Potential Upside/Downside+28.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.33) Trailing P/E RatioN/A Forward P/E Ratio362.16 P/E Growth12.83Net Income$682.64 million Net Margins-22.58% Pretax Margin-28.49% Return on Equity-362.45% Return on Assets-6.76% Debt Debt-to-Equity RatioN/A Current Ratio2.44 Quick Ratio2.36 Sales & Book Value Annual Sales$1.73 billion Price / Sales3.30 Cash Flow$8.78 per share Price / Cash Flow7.84 Book Value($2.18) per share Price / Book-31.56Miscellaneous Outstanding Shares82,950,000Free Float78,387,000Market Cap$5.71 billion OptionableOptionable Beta0.53 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PTCT) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
